Your session is about to expire
← Back to Search
Romiplostim for Thrombocytopenia
Study Summary
This trial is to see if a drug called romiplostim will help raise a patient's platelet counts back to a normal range faster than if the patient just waited for their platelets to improve on their own. The trial will also see if romiplostim will allow the patient to have at least 2 more cycles of chemotherapy without having low platelet counts again.
- Thrombocytopenia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 169 Patients • NCT00907478Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are 18 years or older and have a type of cancer that is currently active and not related to blood.
- Group 1: Romiplostim
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this new research on romiplostim build off of other scientific work?
"romiplostim was first investigated in 2014 at Memorial Sloan Kettering Bergen. 41 studies have completed since then. As of now, 9 clinical trials are ongoing with most of them based in New york City."
Are participants being accepted into this experiment at this time?
"No, this study is not currently recruiting patients according to the most recent update on clinicaltrials.gov. The site reports that the study was first posted on 1/30/2014 and last updated on 2/1/2022. However, there are 132 other trials looking for participants right now."
Has this type of clinical trial been done before?
"There have been a total of 9 ongoing studies for romiplostim since 2014. Earlier trials, such as the one sponsored by Amgen, completed their Phase 2 drug approval stage in 60 participants. More recent 41 trials are being conducted across 62 cities and 23 countries."
How many people are allowed to enroll in this clinical trial?
"This particular trial is not taking any more participants at this time. The study was originally posted on 1/30/2014, with the latest update being 2/1/2022. There are currently 123 trials actively recruiting participants with thrombocytopenia and 9 studies for romiplostim actively looking for patients."
In how many different research facilities is this trial being run today?
"There are presently 6 sites where this trial is taking place. They are based in New york, Harrison and Basking Ridge as well as other cities. Keep in mind that if you want to participate it might be best to select the clinic closest you, to minimize travel requirements."
Is there a potential for serious harm to patients who take romiplostim?
"Romiplostim's safety is unproven but there is some data supporting its efficacy, so it received a score of 2."
Share this study with friends
Copy Link
Messenger